Powered by

Dendreon gets unexpected $15M bump in sale price to $415M

Feb 20, 2015 - The Deal Pipeline
Mergers and Acquisitions

In an eleventh-hour deal, Dendreon Corp. (DNDNQ) will sell its rights to prostate cancer drug Provenge, $80 million in cash and other assets for more than anticipated. Judge Laurie Selber Silverstein of the U.S. Bankruptcy Court for the District of Delaware in Wilmington entered a Friday, Feb. 20, order approving a $415 million sale of the Seattle biotechnology company's assets to a subsidiary of original stalking-horse bidder Valeant Pharmaceuticals International Inc. (VRX) of Laval, Queb...